Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083368 | 0.76 | PKM (0.47) | HRH3HRH4PKMKDM4EPOLB | |
| SCHEMBL27170360 | 0.74 | ADRA1D (0.46) | HRH3HRH4ADRA1D | |
| SCHEMBL2841402 | 0.71 | — | — | |
| SCHEMBL7426757 | 0.70 | HRH4 (0.46) | HRH4HRH1 | |
| SCHEMBL233717 | 0.69 | — | — | |
| SCHEMBL2631880 | 0.69 | MPG (0.52) | HRH3HRH4 | |
| SCHEMBL20131388 | 0.69 | MPG (0.52) | HRH3HRH4 | |
| SCHEMBL21306102 | 0.69 | PKM (0.44) | HRH3HRH4PKMKDM4EPOLB | |
| SCHEMBL18839725 | 0.69 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL7047906 | 0.69 | HRH3 (0.41) | HRH3HRH4PKMKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776408-B1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-11-06 | — | — | EP | disclosed |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9303029-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-29 | — | — | US | disclosed |
| WO-2013061081-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| US-7763644-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. | 2008-04-03 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| EP-0915875-B1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2003-04-09 | — | — | EP | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220564-A1 | SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | HRH3 1226/4885HRH4 711/4885PKM 923/4885 |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | HRH3 753/4885HRH4 322/4885PKM 709/4885 |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR4, FGFR3 | HRH3 2224/4885HRH4 1488/4885PKM 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.